RTX-GRT7039 Injection for Osteoarthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a special injection called RTX-GRT7039 to help reduce knee pain in people with osteoarthritis who still have pain despite usual treatments. The injection works by blocking pain signals from the knee.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
How is RTX-GRT7039 different from other osteoarthritis treatments?
What data supports the effectiveness of the treatment RTX-GRT7039 Injection for Osteoarthritis?
Are You a Good Fit for This Trial?
Adults over 18 with knee osteoarthritis who haven't found pain relief from standard treatments can join. They must understand and agree to the trial's process. Excluded are those with severe joint damage, past knee surgery within a year, significant leg misalignment, other conditions affecting safety or results, recent participation in another drug trial, employees involved in the study, clinical hip osteoarthritis on the same side, or allergy to resiniferatoxin.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single intra-articular injection of RTX-GRT7039 or placebo during the 52-week double-blind treatment period
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Placebo
- RTX-GRT7039
Find a Clinic Near You
Who Is Running the Clinical Trial?
Grünenthal GmbH
Lead Sponsor
Gabriel Baertschi
Grünenthal GmbH
Chief Executive Officer since 2016
Biology degree from the University of Neuchâtel
Prof. Dr. Uli Brödl
Grünenthal GmbH
Chief Medical Officer
MD from Ludwig-Maximilians University Munich